Investigator |
Title |
Sponsor |
ID |
Dates |
Amount |
Ralph A Gruppo, MD |
Hemophilia Comprehensive Care |
Maternal & Child Health Bureau (Hemophilia Foundation of Michigan) |
H30MC00015 |
10/1/1997 - 5/31/2016 |
$22,000 |
Ralph A Gruppo, MD |
Zimmerman Program for the Molecular and Clinical Biology of VWD |
National Institutes of Health (Medical College of Wisconsin) |
P01 HL081588 |
2/1/2013 - 1/31/2017 |
$200 |
Ralph A Gruppo, MD |
MY Life, Our Future: A Hemophilia Genotyping Initiative |
American Thrombosis & Hemostatis Network |
ATHN2014MLOF2 |
2/1/2014 - 9/30/2017 |
$1,850 |
Theodosia A Kalfa, MDPHD |
Rho GTPases in Terminal Erythroid Maturation |
National Institutes of Health |
R01 HL116352 |
9/26/2012 - 6/30/2017 |
$376,762 |
Karen Ann Kalinyak, MD |
The Mid-South Clinical Data Research Network |
Patient-Centered Outcome Research Inst. (Vanderbilt University) |
CDRN1306048691 |
7/1/2014 - 6/30/2016 |
$525 |
Patrick McGann, MD-MS |
Therapeutic Response Evaluation and Adherence Trial: A Prospective Study of Hydroxyurea for Children with Sickle Cell Anemia |
National Institutes of Health |
K23 HL128885 |
9/1/2015 - 5/31/2020 |
$345,870 |
Eric Mullins, MD |
Mechanisms Linking Hemostatic Factors to Neuroinflammatory Disease |
National Institutes of Health |
K08 HL105672 |
8/22/2011 - 7/31/2016 |
$131,085 |
Joseph S Palumbo, MD |
Hemostatic Factors Drive Prostate Cancer Pathogenesis |
National Institutes of Health |
R01 CA193678 |
4/15/2016 - 3/31/2021 |
$356,850 |
Joseph S Palumbo, MD |
Coagulation Factors as modifiers of the Colon Cancer Microenvironment |
National Institutes of Health |
R01 CA204058 |
4/5/2016 - 3/31/2021 |
$356,850 |
Lisa M Shook |
Cincinnati Sickle Cell Project |
Health Resources & Services Admin (Ohio Department of Health) |
03130011SK0512 |
7/1/1998 - 6/30/2016 |
$123,469 |
Lisa M Shook |
Sickle Cell Treatment Demonstration Program |
Health Resources & Services Admin |
U1EMC27863 |
9/1/2014 - 8/31/2017 |
$850,000 |
Russell Ware, MD-PHD |
Genetic Variants Influencing the Phenotypic Expression of Sickle Cell Anemia |
Doris Duke Charitable Foundation |
2015132 |
9/1/2015 - 8/31/2018 |
$162,000 |
Russell Ware, MD-PHD |
Prospective Analysis of the Pharmacokinetics and Pharmacodynamics of Hydroxyurea Treatment in Ugandan Children with Sickle Cell Anemia |
Doris Duke Charitable Foundation |
2015190 |
11/1/2015 - 10/31/2017 |
$56,000 |
Russell Ware, MD-PHD |
Genetic Variants Influencing the Phenotypic Expression of Sickle Cell Anemia |
Doris Duke Charitable Foundation |
2016074 |
6/1/2016 - 11/30/2017 |
$70,400 |
Russell Ware, MD-PHD |
Endothelialized Microfluidics for Sickle Cell Disease Research & Drug Discovery |
National Institutes of Health (Emory University) |
R01 HL121264 |
1/1/2014 - 12/31/2018 |
$18,374 |
Russell Ware, MD-PHD |
Accurate and Inexpensive Point-of-Care Diagnosis of Sickle Cell Anemia |
Doris Duke Charitable Foundation (Rice University) |
R06981 |
9/1/2013 - 8/31/2016 |
$48,930 |
Russell Ware, MD-PHD |
Genetic Modifiers of Transfusional Iron Overload |
National Institutes of Health (Baylor College of Medicine) |
R21 HL123641 |
8/1/2015 - 7/31/2017 |
$17,979 |
Total Annual Grant Award Dollars |
$2,939,144 |